Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with Alzheimer’s drug technology.
The biotech has entered into a licensing and collaboration agreement with Swedish company AlzeCure Pharma for rights to the latter’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. QuantumCell is paying only $12m upfront, but a tail-heavy weighting to the deal with milestone payments means the total transaction could exceed $2.2bn.
The upfront fee itself also includes a $5m direct investment in AlzeCure, at a 30% premium to AlzeCure’s average share price over the last 10 trading days.
NeuroRestore develops small-molecule drugs designed to improve cognitive functions, like learning and memory, in patients with cognitive disorders, though its primary focus is currently Alzheimer’s disease.
ACD856 is a small-molecule positive modulator of both NGF/TrkA and BDNF/TrkB mediated signalling (Trk-PAM). Trk receptors are located on neurons and are critical for synaptic strength and plasticity. According to AlzeCure, ACD856 has already shown neuroprotective, anti-inflammatory and disease-modifying effects in several preclinical models.
In Phase Ib data published in June 2026, ACD856 was safe and well-tolerated when given repeatedly at higher doses than previously tested. At the time, AlzeCure’s chief medical officer Märta Segerdahl said: “An expected increase in the concentration of ACD856 was seen in both blood and cerebrospinal fluid. These data further strengthen the continued development of ACD856, broaden the therapeutic window, and provide a solid foundation for dose selection in future clinical studies.”
QuantumCell has not revealed the indications it plans to pursue with ACD856. Indeed, the biotech has kept much of its business strategy and R&D in the shadows.
QuantumCell emerged onto the biotech scene in December 2025 with backing from Lundbeckfonden and Novo Holdings. Its high-profile venture capital investors hint at how the biotech was able to strike such a large deal relatively early on in its lifecycle.
On its LinkedIn page, the company describes itself as a “dynamic biology company on a mission to decode and defeat the most complex brain disorders of our time. By converging next-generation sensing technologies, autonomous robotics, and cutting-edge AI, we are building the world’s first high-fidelity virtual cell and virtual system model: a mechanistically anchored simulation of human biology that can predict how drugs will behave in a patient before a single trial is run.”
The QuantumCell marks the second out-licensing transaction by AlzeCure this year. In June, Eli Lilly outlaid up to $1bn to secure rights to the Swedish pharma’s ACD680, another candidate in development for the treatment of Alzheimer’s.
by Robert Barrie
Source: pharmaceutical-technology.com
Under a new five-year agreement, Haleon plans wider adoption of AI-powered tools to help employees “automate routine tasks, collaborate more effectively and focus on higher-value work,” the London-based company said in a July 1 announcement days after Microsoft revealed the deal. The Advil maker already used Microsoft 365 Copilot before the latest relationship upgrade.
With over 25 years of experience in the international CDMO and biotechnology industries, Torsten Woehr combines strong leadership skills in the commercial sector with in-depth knowledge of operational business. Most recently, he served as Chief Commercial Officer of Bachem, where he led global business operations and drove key strategic investments.
IMCD Group, a global partner for the distribution and formulation of speciality chemicals and ingredients, has opened its new Pharmaceutical Technical Centre and Food & Nutrition US Technical Hub in IMCD’s new offices in Allendale, New Jersey, USA. The new facilities are part of IMCD’s network of more than 80 technical centres globally.
